Retatrutide research has moved beyond the early obesity study that still dominates many online summaries. By 31 October 2026, the evidence includes published phase 3 trials as well as newer company announcements. Reading those sources together requires more care than choosing the largest weight-loss percentage. Study population, analysis method and clinical endpoint can change what a headline actually means.
Retatrutide is described as investigational in Lilly’s latest announcement. Its programme spans body weight, glycaemic control and symptom outcomes across several clinical populations. Latest programme update.
What the earlier study established
The 2023 phase 2 trial enrolled 338 adults. It provided human evidence for a molecule acting at GIP, GLP-1 and glucagon receptors, rather than simply a theoretical argument for combining these targets. At 48 weeks, the highest studied group had an average weight reduction of 24.2%, compared with 2.1% for placebo. Gastrointestinal events were common, and the investigators also observed dose-dependent heart-rate increases that peaked before declining. Those findings justified larger studies; a relatively small trial could not settle uncommon or long-term harms. Phase 2 publication.
TRIUMPH-1 is now a published result
The September 2026 paper reports 2,339 participants without diabetes followed for 80 weeks. In the highest studied group, mean weight change was −25.0%, versus −3.9% with placebo, using the treatment-regimen analysis. The paper reports an estimated between-group difference of −21.0 percentage points. It also examined knee-pain and sleep-apnoea outcomes in defined subgroups; those results should not be generalised to everyone in the trial. Gastrointestinal events remained the most frequent adverse events. TRIUMPH-1 publication.
A treatment-regimen analysis asks about assignment to treatment while accounting for events such as discontinuation. An efficacy analysis answers a different, more adherence-focused question. Neither label should be stripped away when reporting a result. Combining the treatment result from one analysis with the placebo result from another produces a comparison that the investigators did not make.
Diabetes and cardiovascular disease are distinct settings
TRIUMPH-2 is also peer-reviewed, with publication in September 2026. It randomised 1,152 adults with overweight or obesity and type 2 diabetes. This is an important extension of the programme because findings in people without diabetes are not automatically transferable to a population with established dysglycaemia and background glucose-lowering treatment. The trial specifically evaluates body weight and glycaemic outcomes in that setting. Its existence strengthens the evidence base, but it does not make results from different populations interchangeable. TRIUMPH-2 publication.
The July sponsor report for TRIUMPH-3 concerns 1,949 participants with severe obesity and cardiovascular disease. It reports 22.6% weight reduction versus 3.2% with placebo at 80 weeks under the efficacy analysis. Crucially, its prespecified five-component cardiovascular analysis had a hazard ratio of 0.82 with a 95% confidence interval of 0.55–1.22. That interval crosses 1: this report does not establish cardiovascular-event superiority. Improvements in weight or risk factors cannot fill that evidential gap. TRIUMPH-3 sponsor report.
Symptoms, biomarkers and comparisons answer different questions
TRIUMPH-4 investigated obesity with knee osteoarthritis. Lilly’s December 2025 announcement reported 28.7% weight reduction versus 2.1% with placebo at 68 weeks in the highest studied group, alongside improvement in a knee-pain score. This was a sponsor topline report. Pain relief is a clinically meaningful question, but it is not direct evidence that cartilage regenerated or that structural joint damage was reversed. Such claims would need different measurements. TRIUMPH-4 announcement.
The newest verified update, dated 28 October 2026, is TRANSCEND-T2D-2. Lilly reports an 80-week comparison with injectable semaglutide in type 2 diabetes: mean HbA1c change was −2.2 versus −1.8 percentage points. This is a company announcement, not a substitute for a full paper. It should not be presented as a retatrutide-versus-tirzepatide result; the release describes that separate comparison, TRIUMPH-5, as ongoing. October head-to-head announcement.
What to look for next
- Complete methods and safety tables for results initially released by the sponsor.
- Consistent reporting of discontinuation, missing data and the chosen analysis.
- Dedicated evidence for cardiovascular events, durability and uncommon harms.
The strongest reading is therefore specific: the programme now contains substantial human efficacy evidence, while publication status and remaining questions differ by trial. Scientific progress is better captured by that map than by a single record-setting number.
Continue with How to read a clinical trial for a closer look at interpreting research evidence.
Sources and further reading
- Retatrutide phase 2 obesity trial — Peer-reviewed randomised human trial; 2023-06-26.
- TRIUMPH-1: Retatrutide for treatment of obesity — Peer-reviewed phase 3 human trial; 2026-09-29.
- TRIUMPH-2: Retatrutide in obesity and type 2 diabetes — Peer-reviewed phase 3 human trial; 2026-09-29.
- Lilly TRIUMPH-2 and TRIUMPH-3 topline release — Sponsor topline announcement; 2026-07-23.
- Lilly TRIUMPH-4 topline release — Sponsor topline announcement; 2025-12-11.
- Lilly TRANSCEND-T2D-2 topline release — Sponsor topline announcement; 2026-10-28.
